A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients
1996

Tamoxifen and Melatonin for Metastatic Tumors

Sample size: 25 publication Evidence: low

Author Information

Author(s): P Lissoni, F Paolorossi, G Tancini, A Ardizzoni, S Barni, F Brivio, GJM Maestroni, M Chilelli

Primary Institution: Divisione di Radioterapia, Locarno, Switzerland; Oncologica, San Gerardo Hospital, Monza, Milan, Italy

Hypothesis

Can the combination of tamoxifen and melatonin enhance anti-tumor efficacy in metastatic solid tumor patients?

Conclusion

The combination of tamoxifen and melatonin may provide some benefit in controlling cancer cell proliferation and improving performance status in untreatable metastatic solid tumor patients.

Supporting Evidence

  • Three patients had a partial response, and thirteen had stable disease.
  • Performance status improved in 9 out of 25 patients.
  • Survival longer than 1 year was observed in 7 out of 25 patients.

Takeaway

This study tested a new treatment using two drugs, tamoxifen and melatonin, to help patients with hard-to-treat cancers feel better and possibly slow down their cancer.

Methodology

Patients received tamoxifen and melatonin orally until disease progression, with clinical responses evaluated through radiological staging and laboratory tests.

Limitations

The small sample size and diverse tumor types limit the ability to draw definitive conclusions.

Participant Demographics

Median age was 64 years, with a male-to-female ratio of 10:15.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% confidence limits 2-24%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication